Program
ozureprubart
Also written as “JYB1904” and “RPT904”.
Its studies are mostly in Chronic Urticaria · Immune System Diseases · Asthma · Rhinitis, Allergic, Perennial, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jemincare | 64 open or running | phase 3since Jan 28, 2026 | Jun 29, 2022 | Jun 7, 2027phase 3 · NCT07402213 |
| GlaxoSmithKline | 11 open or running | phase 2since Oct 22, 2025 | Oct 22, 2025 | Mar 16, 2027phase 2 · NCT07220811 |
- Named in GlaxoSmithKline’s own pipeline as
ozureprubart GSK6775388
, phase 2, as of Sep 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 29, 2022First study: phase 1 study in HealthyNew to JemincareJemincare · NCT05449535 · 56 enrolled · China
- May 27, 2024Phase 2 study in Allergic AsthmaJemincare · NCT06438757 · 69 enrolled · China
- Jun 27, 2024Phase 2 study in Chronic UrticariaJemincare · NCT06509334 · 135 planned · China
- Oct 22, 2025GlaxoSmithKline's first study: phase 2 study in Immune System DiseasesNew to GlaxoSmithKlineGlaxoSmithKline · NCT07220811 · 110 enrolled · United States, Australia, Canada
- Jan 28, 2026Phase 3 study in Chronic UrticariaPhase 3 reachedJemincare · NCT07402213 · 240 planned · China
- Feb 27, 2026Phase 2 study in Rhinitis, Allergic, PerennialJemincare · NCT07459452 · 135 planned
- Mar 27, 2026Phase 1 study in Allergic DiseasesJemincare · NCT07513857 · 12 planned
Ahead
- Mar 16, 2027Primary completion: phase 2 study in Immune System DiseasesGlaxoSmithKline · NCT07220811
- Jun 7, 2027Primary completion: phase 3 study in Chronic UrticariaJemincare · NCT07402213
- Jul 30, 2027Primary completion: phase 1 study in Allergic DiseasesJemincare · NCT07513857
- Oct 2027Primary completion: phase 2 study in Rhinitis, Allergic, PerennialJemincare · NCT07459452
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07513857Allergic Diseases | 1 | Not yet recruiting | Jemincare | Jul 30, 2027 | 12 |
| NCT07459452Rhinitis, Allergic, Perennial | 2 | Not yet recruiting | Jemincare | Oct 2027 | 135 |
| NCT07402213Chronic Urticaria · China | 3 | Recruiting | Jemincare | Jun 7, 2027 | 240 |
| NCT07220811Immune System Diseases · United States, Australia, Canada | 2 | Active, not recruiting | GlaxoSmithKline | Mar 16, 2027 | 110 |
| NCT06509334Chronic Urticaria · China | 2 | Recruiting | Jemincare | Jul 15, 2026 | 135 |
| NCT06438757Allergic Asthma · China | 2 | Completed | Jemincare | Nov 20, 2025 | 69 |
| NCT05449535Healthy · China | 1 | Completed | Jemincare | Jan 10, 2023 | 56 |
How it is read
Names in the registry
- “JYB1904”, 8 entries
- “RPT904”, 4 entries
Conditions, from the studies’ own filings
- Chronic Urticaria, 2 studies
- Immune System Diseases, 1 study
- Asthma, 1 study
- Rhinitis, Allergic, Perennial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.